miR-140 inhibits osteosarcoma progression by impairing USP22-mediated LSD1 stabilization and promoting p21 expression

Liu, Wei; Wang, Dunwei; Liu, Lidi; Wang, Lin; Yan, Mingxia

doi:10.1016/j.omtn.2021.01.029

Cited by 18 publications

(12 citation statements)

References 30 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al. also found that miR-140 attenuated osteosarcoma progression via interference of USP22-involved lysine-specific demethylase 1 (LSD1) stabilization and elevating p21 expression ( 40 ). We also confirmed that USP22 enhanced viability and motility of osteosarcoma cells.…”

Section: Discussionmentioning

confidence: 99%

Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

et al. 2022

View full text Add to dashboard Cite

Osteosarcoma is one of the bone malignancies in children and adolescents. Long noncoding RNAs (lncRNAs) have been demonstrated to participate in osteosarcoma development and progression. Linc00265 has been shown to involve in osteosarcoma oncogenesis; however, the underlying mechanism is largely unclear. In this study, we investigated the function of linc00265 in osteosarcoma cells, including cell viability, migration and invasion. Moreover, we elucidated mechanistically the involvement of linc00265 in osteosarcoma. We found that linc00265 overexpression promoted viability, migration and invasion of osteosarcoma cells. Notably, linc00265 sponged miR-485-5p and increased the expression of USP22, one target of miR-485-5p, in osteosarcoma cells. Strikingly, linc00265 exerted its oncogenic function via regulating miR-485-5p and USP22 in osteosarcoma. Taken together, targeting linc00265 is a promising approach for treating osteosarcoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mickymaray et al found that rhaponticin can inhibit OS growth by inhibiting the PI3K-Akt-mTOR pathway [25]. Liu et al reported that miR-140 inhibits OS development by influencing ubiquitin-specific protease 22 and promoting p21 expression [26].…”

Section: Discussionmentioning

confidence: 99%

Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma

Zhang

Wang

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Purpose Osteosarcoma (OS) is a differentiation disease caused by the genetic and epigenetic differentiation of mesenchymal stem cells into osteoblasts. OS is a common, highly malignant tumor in children and adolescents. Fifteen to 20 % of the patients find distant metastases at their first visit. The purpose of our study was to identify biomarkers for tracking the prognosis and treatment of OS to improve the survival rate of patients. Materials and methods In this study, which was based on Therapeutically Applicable Research to Generate Effective Treatments (TARGET), we searched for m6A related lncRNAs in OS. We constructed a network between lncRNA and m6A, and built an OS prognostic risk model. Results We identified 14,581 lncRNAs by using the dataset from TARGET. We obtained 111 m6A-related lncRNAs through a Pearson correlation analysis. A network was built between lncRNA and m6A genes. Eight m6A-related lncRNAs associated with survival were identified through a univariate Cox analysis. A selection operator (LASSO) Cox regression was used to construct a prognostic risk model with six genes (RP11-286E11.1, LINC01426, AC010127.3, DLGAP1-AS2, RP4-657D16.3, AC002398.11) obtained through least absolute shrinkage. We also discovered upregulated levels of DLGAP1-AS2 and m6A methylation in osteosarcoma tissues/cells compared with normal tissues/osteoblasts cells. Conclusion We constructed a risk score prognosis model of m6A-related lncRNAs (RP11-286E11.1, LINC01426, AC010127.3, DLGAP1-AS2, RP4-657D16.3, AC002398.11) using the dataset downloaded from TRAGET. We verified the value of the model by dividing all samples into test groups and training groups. However, the role of m6A-related lncRNAs in osteosarcoma needs to be further researched by cell and in vivo studies.

show abstract

“…LSD1 function in osteosarcomas is complex with many layers of regulation that are all disrupted when LSD1 is overexpressed. For example, in osteosarcoma LSD1 demethylates the p21 promoter, decreasing p21 expression and thus promoting cell cycle progression ( 78 ) ( Figure 2B ). USP22, an ubiquitin specific protease, stabilizes the LSD1/p21 interaction and facilitates the downregulated expression of p21.…”

Section: Lsd1 In Sarcomasmentioning

confidence: 99%

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Dreher

Theisen

2023

Front. Oncol.

View full text Add to dashboard Cite

Sarcomas are a diverse group of tumors with numerous oncogenic drivers, and display varied clinical behaviors and prognoses. This complexity makes diagnosis and the development of new and effective treatments challenging. An incomplete understanding of both cell of origin and the biological drivers of sarcomas complicates efforts to develop clinically relevant model systems and find new molecular targets. Notably, the histone lysine specific demethylase 1 (LSD1) is overexpressed in a number of different sarcomas and is a potential therapeutic target in these malignancies. With the ability to modify histone marks, LSD1 is a key player in many protein complexes that epigenetically regulate gene expression. It is a largely context dependent enzyme, having vastly different and often opposing roles depending on the cellular environment and which interaction partners are involved. LSD1 has been implicated in the development of many different types of cancer, but its role in bone and soft tissue sarcomas remains poorly understood. In this review, we compiled what is known about the LSD1 function in various sarcomas, to determine where knowledge is lacking and to find what theme emerge to characterize how LSD1 is a key molecular driver in bone and soft tissue sarcoma. We further discuss the current clinical landscape for the development of LSD1 inhibitors and where sarcomas have been included in early clinical trials.

show abstract

miR-140 inhibits osteosarcoma progression by impairing USP22-mediated LSD1 stabilization and promoting p21 expression

Cited by 18 publications

References 30 publications

Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

Contact Info

Product

Resources

About